Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 – 2032
- Published Date:May-2024
- Pages: 118
- Format: PDF
- Report ID: PM4913
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
Cancer cachexia market revenue was valued at USD 2.41 billion in 2023. The market is anticipated to grow from USD 2.48 billion in 2024 to USD 3.43 billion by 2032, exhibiting the CAGR of 4.2% during the forecast period.
Market Overview
The emergence of cancer cachexia is a serious condition all over the world because it consumes many sources of energy, such as adipose tissue and skeletal muscle. It adversely affects the ability of patients to fight against the infection and also withstand ongoing treatments, including radiotherapy and chemotherapy. Thereby, leading healthcare companies and research institutes are heavily focusing on determining the causes of cachexia and developing solutions to address this health issue.
- For instance, in April 2023, Researchers at UCL and Francis Crick Institute were able to identify the causes behind cachexia. Also, researchers found a high correlation with the levels of GDF15 in human blood, which is able to manage cancer cachexia or even prevent it completely.
Furthermore, the management of cancer cachexia has significantly advanced over the years with the emergence of pharmacological perspective & diagnostic-prognostic criteria. Several pharmacological agents, such as non-steroidal anti-inflammatory drugs, appetite stimulants, anabolic agents, & Beta-blockers, have proven efficacy in the treatment of cancer cachexia.
To Understand More About this Research: Request a Free Sample Report
Growth Factors
Increasing prevalence of cancer cachexia cases to drive global market growth
The rapid increase in the prevalence of cancer cachexia across the globe and the substantial increase in the aging population who are more susceptible to cancer are key factors fostering the market’s growth. Cancer cachexia market drivers include factors such as decreased nutrient absorption, increased fat and protein breakdown, and metabolic dysregulation, among others. For instance, as per a recent report by PubMed Central, around 9 million people worldwide are affected with cancer cachexia, and it is predicted that 20% of cancer deaths are caused by the effect of cachexia among 50-80% of cancer patients.
Rising investments in R&D activities spurring market growth
The surging incidence of cancer cachexia among cancer patients globally led to increased focus of healthcare organizations and private companies towards R&D investments and developing new products with enhanced capabilities and characteristics, lead to the cancer cachexia market growth. For instance, in June 2023, Actimed Therapeutics, announced that they have raised over £5 million for advancing the lead program for cancer cachexia. This investment is raised with the purpose of supporting the development of S-pindolol benzoate targeted at cancer cachexia treatment in non-small cell lung cancer.
Restraining Factors
High treatment costs and stringent regulations restrict the market’s growth
The high cost associated with the treatment of cancer cachexia and the presence of stringent government regulations & reimbursement for therapeutics in developing nations is hampering global market growth. Additionally, treatment of cancer cachexia might also have some side effects that negatively impact their effectiveness and tolerability among patients, which, in turn, hinders the market’s growth.
Report Segmentation
The market is primarily segmented based on therapeutics, mechanism of action, distribution channel, and region.
|
By Therapeutics |
By Mechanism of Action |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Therapeutics Insights
Progestogens segment accounted for the largest market share in 2023
The progestogens segment accounted for the largest cancer cachexia market share in 2023. This dominance is accelerated by the low cost of progestogens as compared to other therapeutics and greater efficiency in the treatment of cancer cachexia. Additionally, progestogens have anti-inflammatory properties that help mitigate the inflammatory processes that contribute to the development of cachexia.
The combination therapy segment will grow at the highest pace. This growth is attributed to a rapid increase in the popularity of multimodal treatment among cachexia patients globally and its ability to address several aspects of cancer cachexia, including inflammation and metabolic alterations.
By Mechanism of Action Insights
Appetite stimulators segment held a significant market size in 2023
The appetite stimulators segment held the majority share in the cancer cachexia market size in 2023. Segment’s dominance is attributed to their increasing use by cancer patients as they frequently develop weight loss as well as loss of appetite. Appetite stimulators are increasingly used to boost food intake and weight gain and help patients maintain a healthy body mass and posture.
In addition, a growing number of research initiatives focused on the creation and development of potential appetite stimulators is expected to raise the market demand for the segment. For instance, in May 2023, researchers at MIT announced the development of a capsule that is able to produce endocrine cells to produce ghrelin, which helps in appetite stimulation.
By Distribution Channel Insights
Online pharmacy segment is expected to witness the highest growth
The online pharmacy segment categorized under the distribution channel is predicted to grow at the highest CAGR during the forecast period. Segment’s cancer cachexia market demand is attributable to the rapid emergence of various online pharmacies as they offer greater convenience to patients to access medication and different medical care products. Also, online pharmacies are gaining traction due to their ability to facilitate the management as well as submission of prescriptions and help patients in the process of obtaining required medications for cancer cachexia.
Regional Insights
North America region dominated the global market in 2023
The North America region dominated the global market. Region’s dominance is attributed to numerous factors such as the rising prevalence of cancer, continuous increase in healthcare budgets, and a number of favorable government initiatives aiming to provide effective treatment options. For instance, according to a report by the American Cancer Society, the number of new cancer deaths in the United States in the year 2022 was approx. 1.9 million and 609,360 respectively.
The Asia Pacific region is anticipated to emerge as the fastest growing region, owing to the increasing population burden and the focus of several governments on establishing well-developed healthcare infrastructure in the region. Also, rapid urbanization and significant lifestyle changes of people in the region have led to a substantial increase in cancer incidences and propelled cancer-associated complications. For instance, according to a report published by the UN, the urban population in India was estimated to be around 675 million in 2035, with a massive increase from 483 million in 2020.
Key Market Players & Competitive Insights
Growing R&D activities and new drug development to drive competition
The cancer cachexia market is moderately competitive in nature due to presence of numerous rivals in the global market. Leading cancer cachexia manufacturers are increasingly investing in research & development activities for the creation of new drugs and formulations and also implementing on different market growth strategies like partnerships, collaborations, acquisitions, and strategic alliances to stay competitive in the market.
Some of the major players operating in the global market include:
- AbbVie Inc. (US)
- Actimed Therapeutics (UK)
- Aeterna Zentaris Inc. (Canada)
- ANI Pharmaceuticals Inc. (US)
- Aphios Corporation (US)
- Aveo Pharmaceuticals Inc. (US)
- Bristol-Myers Squibb Company (US)
- Helsinn Group (Switzerland)
- Hikma Pharmaceuticals PLC (UK)
- Merck & Co. Inc. (US)
- Mylan N.V. (US)
- Pfizer Inc. (US)
- TCI Peptide Therapeutics (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
Recent Developments in the Industry
- In January 2024, Meta Fines announced that they had signed a licensing-out agreement with BMI Korea for their cancer cachexia drug ASCA101_CC. According to this agreement, BMI Korea will hold the rights of global technology transfer of ASCA101_CC along with Meta Fines and will also have the right to license products in a few countries.
- In January 2023, Endevica Bio closed a USD 10 million Series B financing for the advancement or development of TCMC07 for treating cancer cachexia. The funding will allow the company to advance its research & development capabilities and help it develop a treatment for the patient population suffering from cachexia.
Report Coverage
The cancer cachexia market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, cancer cachexia market trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative cancer cachexia market analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The cancer cachexia market report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, therapeutics, mechanism of action, distribution channel, and their futuristic growth opportunities.
Cancer Cachexia Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 2.48 billion |
|
Revenue forecast in 2032 |
USD 3.43 billion |
|
CAGR |
4.2% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
The global cancer cachexia market size is expected to reach USD 3.43 billion by 2032
Key players in the market are Aeterna Zentaris, ANI Pharmaceuticals, Merck & Co. Inc
North America contribute notably towards the global Cancer Cachexia Market
Cancer cachexia market exhibiting the CAGR of 4.2% during the forecast period.
The Cancer Cachexia Market report covering key segments are therapeutics, mechanism of action, distribution channel, and region.
